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KEY MESSAGES
 A hypothetical randomized trial comparing dynamic treatment strategies can be emulated by applying inverse-probability weighting of a dynamic marginal structural model to observational data.
 This approach is facilitated by specifying the protocol of the target trial one would like to emulate in terms of the eligibility criteria, the treatment strategies, the follow-up period, outcomes, causal contrasts of interest, and analysis plan.
 As an example, we apply our approach to compare dynamic switching strategies based on HIV-1 RNA thresholds. In our data, most individuals were doing well on their first-line antiretroviral regimen and no differences between switching at HIV-1 RNA thresholds of 400 and 1,000 copies/mL in preventing death and AIDS-defining illness were detected.
INTRODUCTION
Many clinical decisions involve switching or discontinuing treatment. The most effective switching strategies are dynamic, that is, they involve switching different individuals at different times depending on the evolution of their time-varying covariates. However, very few randomized trials compare two or more dynamic strategies for switching medical treatments.
Despite this lack of clinical evidence, many clinical guidelines provide recommendations in the form of dynamic switching strategies. immediately if HIV-1 RNA > 500-1,000 copies/mL or > 400 copies/mL, respectively (but suggest repeating a viral load measurement if HIV-1 RNA is detectable but below the threshold for switching), and the World Health Organization 5 guidelines recommend waiting to switch until confirmation of HIV-1 RNA > 1,000 copies/mL. This threshold is chosen as it is the lowest level that can be used when measuring viral load from dried blood spots. Tight-control strategies are recommended so as to avoid the use of failing antiretrovirals in the presence of ongoing viral replication which may lead to selection of drug resistant mutations requiring more expensive drugs and limiting future treatment options. [6] [7] [8] [9] Here we review a framework for the comparison of dynamic switching strategies using observational data. [10] [11] [12] [13] [14] We begin by describing the protocol of the hypothetical randomized trial we would like to conduct (the target trial). We then review an approach to emulate this target trial using observational data. To overcome the limitations of standard methods for adjustment for time-varying confounders, 15, 16 we use inverse-probability weighting of a dynamic marginal structural model. 17
THE PROTOCOL OF THE TARGET TRIAL
The target trial is a hypothetical randomized trial that is specified in order to guide our analysis of observational data. Key components of its design are eligibility criteria, treatment strategies being compared, follow-up period, outcomes, causal contrasts of interest, and analysis plan. These were agreed through discussions between colleagues with clinical and statistical backgrounds, which focused on the hypothetical randomized trial whose results would be most useful to resolve uncertainties in clinical practice. We describe each of these components below.
Eligibility criteria
The trial includes individuals who initiated antiretroviral therapy in 2002 or later, achieved suppression of viral replication (defined as at least one measurement of HIV-1 RNA ≤ 200 copies/mL) within 360 days of initiating treatment, and then experienced confirmed virologic failure (defined as the second of two measurements of HIV-1 RNA > 200 copies/mL 7-180 days apart). At confirmed virologic failure (baseline), individuals are required to be 18 years of age or older and have a CD4 cell count measurement in the previous 90 days. Eligible antiretroviral regimens before first virologic failure are listed in Table 1 .
Treatment strategies
Eligible individuals are randomized to either tight-or loose-control strategies at confirmed virologic failure. The tight-control strategy is "switch within 90 days of HIV-1 RNA crossing above 400 copies/mL." The loose-control strategy is "switch within 90 days of HIV-1 RNA crossing above 1000 copies/mL." In both arms, individuals should switch from regimens at baseline to new regimens (as indicated in Table 2 ) and switches are expected to occur uniformly 11 during the 90-day grace period. After the switch, individuals may switch to another regimen or discontinue treatment if clinically indicated or recommended by their treating physicians. However, regardless of the treatment received after switching, all individuals should be seen and have their CD4 cell count/HIV-1 RNA measured on average every 12-16 weeks and at least once every 52 weeks. In this target trial, as in all randomized trials, we expect that some individuals will not adhere to their assigned treatment strategy.
Outcomes
The clinical outcomes of interest are all-cause mortality and a combined endpoint of AIDS-defining illness 18 or death.
Follow-up period
Individuals are followed from baseline (randomization) until the outcome, loss to followup (52 weeks after the most recent laboratory measurement), or the administrative end of followup (3 years after baseline), whichever occurred first.
Causal contrasts of interest
To compare the two switching strategies, we calculate the intention-to-treat effect and the per-protocol effect (i.e., the effect that would have been observed if all participants had switched as indicated in this protocol, regardless of the treatment they received subsequently).
Analysis plan
Intention to treat analysis: We estimate 3-year Kaplan-Meier survival curves by randomization arm. Despite its limitations as an effect measure, 19 we also estimate the mortality hazard ratio via the pooled logistic model logit Pr( +1 = 1| = 0, ) = 0 + 1 , where Dt is an indicator (1: yes, 0: no) for death in week t, 0 is a time-specific intercept (the baseline hazard, estimated via linear and quadratic terms for t), X is an indicator for randomization arm (1: loose-control, 0: tight-control), and 1 is the log odds ratio of mortality for loose-versus tight-control. Because mortality is rare in each time interval, the parameter 1 approximates the log of the intention-to-treat mortality hazard ratio that would have been estimated from a proportional hazards Cox model. 20 In case of a chance imbalance of pre-treatment prognostic factors V between arms, the model would include them as covariates.
Per-protocol analysis: Individuals are censored when they deviate from the switching strategies in this protocol. In particular, individuals are censored at the time they change treatment prematurely (i.e., between baseline and when HIV-1 RNA first crosses above 400 copies/mL for tight control and above 1000 for loose control), change to an ineligible regimen during the 90day grace period, and at the end of the grace period if the individual has not yet switched to an eligible regimen. Because this censoring may be informative, adjustment for both baseline (prerandomization) and time-varying (post-randomization) covariates may be necessary. 11 To estimate the per-protocol average mortality hazard ratio, we fit a weighted model logit where ( | ̅ −1 , = 0, ̅ ) is the conditional probability mass function | ̅ −1 , =0, ̅ ( | ̅ −1 , = 0, ̅ ) with ( | ̅ −1 , = 0, ̅ ) evaluated at the random argument ( | ̅ −1 , = 0, ̅ ) and −1 = 0.
As previously described, 21 these probabilities are estimated using pooled multinomial logistic models including a time-specific intercept (estimated via linear and quadratic terms for t), the baseline covariates previously listed, and the time-varying covariates (CD4 cell count (restricted cubic spline with 5 knots at 10, 200, 350, 500, and 1,000 cells/mm 3 ), HIV-1 RNA (≤400, 401-1,000, >1,000 copies/mL), AIDS-defining illness (when the outcome was death alone), and time since last laboratory measurement (<4, 4-7, 8-11, ≥12 weeks)). For an explanation of why the probability of treatment changes can be used to estimate the probability of remaining uncensored, please see Cain et al. 2010. 11 Under the assumptions that (1) we measured and successfully adjusted for all confounders (i.e., prognostic factors that also predict censoring); (2) there is positivity (i.e., no deterministic treatment assigned given the confounders); and ( To estimate per-protocol survival curves, we fit a similar model that included a product ("interaction") term between X and f(t) where f(t) is a flexible function of time (estimated via linear and quadratic terms for t). The models' predicted values are then used to estimate the 3-
year survival from baseline as previously described. 11, 19 (Nonparametric estimation of survival curves would result in very unstable estimates.)The estimated 3-year survival can be interpreted as the survival that would have been estimated had all individuals switched according to the study protocol (regardless of the treatment they subsequently received).
The same analytic approach is then applied to the combined endpoint of AIDS-defining illness or death. Inverse probability weighting may be used to adjust for potential selection bias due to loss to follow-up 25 in both the intention-to-treat and per-protocol analyses.
EMULATING THE TARGET TRIAL USING OBSERVATIONAL DATA
In the absence of a randomized clinical trial for switching, we emulated one using observational data 22 from the Antiretroviral Therapy Cohort Collaboration (ART-CC), the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS), and the HIV-CAUSAL Collaboration. These collaborations have been described elsewhere. [26] [27] [28] [29] The cohorts that make up these collaborations are listed in Appendix 1. All overlaps between and within collaborations were removed. Each cohort collected data prospectively, including CD4 cell count, HIV-1 RNA (limit of detection ≤ 200 copies/mL), dates of treatment initiation and treatment changes, AIDS-defining illness, and death.
We designed our analysis of the observational data to match the eligibility criteria, the treatment strategies, and the outcomes of the target trial as much as possible.
Eligibility criteria
We applied the same eligibility criteria as in the target trial. Our analysis was restricted to HIV-infected persons who initiated antiretroviral therapy after January 1, 2002 (2004 for CoRIS,   2005 for FHDH and Frankfurt when information on their treatment interruptions became available).
Treatment strategies
We compared the same tight-and loose-control switching strategies as in the target trial.
To reduce the influence of data errors, new drug prescriptions of duration 14 days or less were disregarded when determining the existence of switching. Instead, the time was assigned to the nearest regimen of duration longer than 14 days before the short regimen. In sensitivity analyses, point estimates did not vary (data not shown) for durations of 31 and 62 days, when we assigned the disregarded time to the nearest longer regimen after the short regimen, and when we used an alternative definition of switching (see Table 2 ).
Outcomes
We considered the same two outcomes as in the target trial: all-cause mortality and a combined endpoint of AIDS-defining illness 18 or death. The date of death was identified using a combination of national and local mortality registries and clinical records as described elsewhere, 28 and AIDS-defining illnesses were ascertained by the treating physicians.
Follow-up period
Follow-up started at baseline and ended at the occurrence of the outcome, loss to followup (52 weeks after the most recent laboratory measurement), or the cohort-specific administrative end of follow-up (up to November 2012), whichever occurred first.
Causal contrast of interest
For the reasons explained below, only the per-protocol effect comparing the two switching strategies can be estimated.
Analysis
We used the same pooled logistic model described for the target trial, except that we fitted the model to an expanded data set constructed as follows. Because all individuals had data consistent with both strategies at confirmed virologic failure (baseline), we created an expanded dataset that included two replicates (clones) of each individual, and assigned each replicate to one of the strategies. We censored replicates if and when their data were no longer consistent with their assigned strategy. 17 In particular, replicates were censored if and when the individual changed treatment too soon (i.e., between baseline and when HIV-1 RNA first crossed above 400 (1000) copies/mL), if and when the individual changed to an ineligible regimen during the 90-day grace period, and at the end of the grace period if the individual had not yet switched to an eligible regimen.
A consequence of using grace periods with cloning and censoring is that an intention-totreat effect cannot be estimated because each individual is assigned to all strategies at baseline.
Therefore, a contrast based on baseline assignment (i.e., an intention-to-treat analysis) will compare groups with essentially identical outcomes. Analyses with a grace period at baseline are geared towards estimating a per-protocol effect of a target trial.
The inverse-probability weights were the same as for the target trial except that we added a numerator 11 to emulate uniform switching during the grace period. This numerator equals The emulation of the design and analysis of the alternative trial in which we would not require confirmation of virologic failure was identical, except that baseline was the time of first virologic failure. The inclusion of inverse-probability weights to adjust for censoring at 52 weeks without a laboratory measurement in addition to the previously described weights had little effect on our estimates (results not shown).
All 95% CIs were estimated via a nonparametric bootstrap with 500 samples. All analyses were conducted with SAS 9.4 (SAS Institute, Cary, North Carolina, USA).
RESULTS
Of 43,803 potentially eligible individuals, 2,001 met the baseline inclusion criteria for the mortality analysis and 1,641 for the AIDS or death analysis. The most common reason for being excluded was never experiencing virologic failure after achieving virologic suppression. A flowchart of patients for the mortality analysis is provided in Figure 1 . Table 3 shows the baseline characteristics of the study population for the mortality analysis. Of the 4,002 replicates in the expanded dataset for the mortality analysis, 74% of the tight control group and 68% of the loose control group were censored during follow-up. In the tight control group, 11% were censored for changing treatment prematurely, 14% were censored for changing to an ineligible regimen during the grace period, and 75% were censored for not having switched to an eligible regimen by the end of the grace period. In the loose control group, 23% were censored for changing treatment prematurely, 14% were censored for changing to an ineligible regimen during the grace period, and 63% were censored for not having switched to an eligible regimen by the end of the grace period. Among the uncensored, the median (IQR) As a sensitivity analysis, we also considered an alternative trial in which we did not require confirmation of virologic failure. In this case, baseline becomes the time of first virologic failure (defined as one measurement of HIV-1 RNA > 200 copies/mL) following virologic suppression. Estimated hazard ratios using this definition of baseline were similar (see Appendix 3 for details).
DISCUSSION
We have described how to use observational data to emulate a hypothetical randomized trial comparing different treatment switching strategies. As an illustration, we applied the method to the question of when to switch from a first-line antiretroviral regimen to a new regimen following virologic failure. 31 Our results suggest that there is little difference between switching within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/mL or 1000 copies/mL in terms of preventing short-term death and AIDS-defining illness. However, even after pooling data from three large consortia of HIV cohorts, our effective sample size was small and the effect estimates imprecisely estimated. This was due, in large part, to the strict eligibility criteria of our target trial, which were defined by a panel of clinicians on the basis of the treatment guidelines. Of the 43,803 potentially eligible individuals, 95% were excluded because they did not meet the baseline inclusion criteria. Most individuals excluded were doing well on their first-line antiretroviral regimen and did not experience virologic failure. Had we been able to observe individuals for longer periods of time, more of them would likely have experienced virologic failure and could have been included in our analyses.
Most individuals in our analysis contributed to both arms of the target trial because one cannot generally observe the exact moment at which these HIV-1 RNA thresholds were crossed.
As a result, 59% of individuals crossed both thresholds at baseline (those with baseline HIV-RNA ≤ 400 copies/mL had the potential to cross both thresholds simultaneously later in their follow-up). In the main analysis, 20 of 29 individuals who died and 31 of 43 individuals who developed AIDS or died contributed events to both groups (see Appendix 2 for details). Similar difficulties have been encountered when trying to emulate target trials that compare two dynamic strategies in cancer patients. 31 The validity of our methodology relies on two key assumptions in addition to positivity.
First, we assume there is no unmeasured confounding given the measured covariates, i.e., that all joint predictors of switching and the outcome were included in the estimation of the inverse probability weights. The assumption might not hold, even approximately, if for example prior adherence to treatment and antiretroviral drug resistance remained important predictors of treatment switching and the outcome even after adjustment for the measured covariates (some of which may be viewed as proxies for adherence and resistance). To further protect our estimates from unmeasured confounding, we defined the dynamic treatment strategies in terms of initial switching regardless of subsequent adherence to treatment. Defining the strategies this way makes it unnecessary to adjust for joint determinants of future switching, and is perhaps more clinically meaningful, as at the time of deciding whether or not to switch, future adherence is unknown.
Second, we assumed a correct specification of the model for switching as a function of the measured confounders. To reduce bias due to model misspecification that results in apparent outliers, we truncated the estimated weights at the 99th percentile of the distribution of the estimated weights. 30 Our analyses only focused on the decision to switch regimens after treatment failure, but in practice switching may occur for other reasons, including regimen simplification, toxicity management, and avoidance of teratogenic effects during pregnancy. While the dates of pregnancies were not available for the majority of individuals in this analysis, we restricted the analysis to those who became virologically suppressed and therefore were more likely to adhere and less likely to experience treatment-related toxicities (more common in the early stages of therapy).
We defined our treatment strategies for switching based on HIV-1 RNA viral load only.
The majority of clinical guidelines 1-4 also recommend investigating the reasons for failure, addressing any adherence issues, and performing resistance testing while the individual is on the failing regimen before switching. While data on adherence and the results of resistance testing were not available for the majority of individuals in this analysis, we hope to be able to incorporate these data in the future. These considerations may suggest that even with reasonable eligibility criteria and minimal unmeasured confounding, our target trial was of limited clinical relevance in the populations and periods during which the observational data for our study were collected.
In summary, we described an approach to compare dynamic strategies of treatment switching via censoring and inverse probability weighting. We expect that the methodological approach described here for the comparison of dynamic switching strategies using observational data will serve as an example for future analyses. Future applications may consider switching strategies for which more HIV-infected individuals are eligible and the use of alternative methods for comparing dynamic strategies of treatment switching, including the parametric gformula, that may result in more precise estimates at the expense of additional modeling assumptions. 16 Appendix Figure 1 lists the cohorts from each collaboration and shows any overlaps.
Appendix Table 2 provides the distribution by cohort of the 43,803 individuals at initiation and 2,001 individuals at baseline in the mortality analysis.
APPENDIX 2
The expanded dataset included two replicates (clones) of each individual because all individuals had data consistent with both strategies at confirmed virologic failure (baseline).
Each replicate was assigned to one of the strategies, either tight or loose control. As a result of the expansion, it is possible for an individual to contribute an outcome to one or both strategies.
In Appendix Table 3 displays 
APPENDIX 3
When not requiring confirmation of virologic failure, there were 6,320 individuals who met the baseline inclusion criteria for the mortality analysis and 5,310 for the AIDS or death analysis. Of the 12,640 replicates in the mortality analysis, 76% of the tight control group and 68% of the loose control group were censored. Among the uncensored, the median (IQR) followup time was 82 (35, 157) weeks for the tight control group and 80 (38, 154) weeks for the loose control group.
There were 50 deaths and 68 AIDS or death events in the tight control group, and 63 deaths and 83 AIDS or death events in the loose control group (Appendix Table 4 ). Among those who died, the median (IQR) time to death was 34 (8, 80 ) weeks for the tight control group and 37 (9, 87) weeks for the loose control group. Among those who developed AIDS or died, the median (IQR) time to AIDS or death was 9 (3, 46) weeks for the tight control group and 19 (5, 57 ) weeks for the loose control group. Compared with tight control, the fully-adjusted hazard ratios (95% CI) for loose control were 0.86 (0.55, 1.33) for death and 1.06 (0.79, 1.43) for AIDS or death.
Appendix Figure 2 plots the estimated 3-year survival and 3-year AIDS-free survival when we did not require confirmation of virologic failure. 
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Finally, individuals must change to regimens that do not include any of the following drugs: zalcitabine (DDC), alovudine (ALO), capravirine (CPV), DPC 083 (DPC083), delavirdine (DLV), emivirine (EMV), lodenosine (DDA or LDN), loviride (LOV), mozenavir (MOZ), vicriviroc (VIC), or any unspecified drugs (ART, PI, NNRTI, NRTI). Table 4 .
